Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with rituximab (anti-CD20,
Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney)
transplant will promote longer-term survival of the transplanted kidney.The pilot study
compares the use of rituximab (Rituxan®) + site-specific standard immunosuppression to
placebo + site-specific standard immunosuppression in the treatment of circulating anti-HLA
antibodies in subjects who develop de novo anti-HLA antibodies between 3-36 months after
transplant.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Clinical Trials in Organ Transplantation Cooperative Clinical Trials in Pediatric Transplantation (CCTPT)